Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,206,852 papers from all fields of science
Search
Sign In
Create Free Account
MC 838
Known as:
MC-838
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (2)
Proline
altiopril calcium
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
MC-838 (Moveltipril Calcium) のウサギにおける器官形成期経口投与試験
杉山修
1990
Corpus ID: 101913757
1989
1989
Contribution of the tissue angiotensin converting enzyme to the antihypertensive effect of altiopril calcium (MC‐838) in spontaneously hypertensive rats
K. Kamei
,
Y. Shiraki
,
T. Koga
,
K. Sakai
The Journal of pharmacy and pharmacology
1989
Corpus ID: 46388041
Abstract— The effect of a new orally active angiotensin converting enzyme (ACE) inhibitor, calcium (—)‐N‐[(S)‐3–[(N…
Expand
1988
1988
Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
J. Aono
,
T. Koga
,
T. Yamazaki
,
Y. Shiraki
,
K. Sakai
Archives internationales de pharmacodynamie et de…
1988
Corpus ID: 27968120
The antihypertensive effects of altiopril calcium (MC-838), calcium(-)-N-[(S)-3-[(N-cyclohexylcarbonyl-D-alanyl)thio]-2-methyl…
Expand
1988
1988
Comparative cardiovascular effects of a novel angiotensin converting enzyme inhibitor altiopril calcium (MC-838) and captopril in spontaneously hypertensive rats.
M. Akima
,
Y. Shiraki
,
K. Sakai
Archives internationales de pharmacodynamie et de…
1988
Corpus ID: 3172420
The cardiovascular effects of a newly developed angiotensin converting enzyme (ACE) inhibitor, calcium(-)-N-[(S)-3-[(N…
Expand
1988
1988
A radioimmunoassay for MC-838 (altiopril calcium), a novel angiotensin-converting enzyme inhibitor.
Y. Hinohara
,
S. Tanaka
,
K. Wakabayashi
Journal of Pharmacobio-Dynamics
1988
Corpus ID: 33826399
A radioimmunoassay was developed for a new, potent inhibitor of angiotensin-converting enzyme (ACE; EC 3.4.15.1), calcium(-)-N…
Expand
1988
1988
Chronotropic and inotropic effects of a new angiotensin converting enzyme inhibitor, MC-838 (altiopril calcium), on the dog heart.
S. Chiba
,
Y. Furukawa
,
K. Saegusa
,
Y. Ohba
Japanese Heart Journal
1988
Corpus ID: 33780228
The effects of calcium (-)-N-[(S)-3(N-cyclohexylcarbonyl-D-alanyl)-thio]-2-methylpropion] -L- prolinate (MC-838, altiopril…
Expand
1988
1988
Tissue angiotensin-converting enzyme blockade by MC-838 (altiopril calcium) infused intravenously to miniature pigs: comparison with captopril.
K. Sakai
,
Y. Shiraki
,
+5 authors
Y. Tohira
Archives internationales de pharmacodynamie et de…
1988
Corpus ID: 25434540
The effect of a new orally active angiotensin-converting enzyme (ACE) inhibitor, calcium(-)-N-[(S)-3-[(N-cyclohexyl-carbonyl-D…
Expand
1987
1987
MC-838 (altiopril calcium): a novel orally active angiotensin converting enzyme inhibitor.
K. Sakai
,
J. Aono
,
+4 authors
K. Kuromaru
Tohoku journal of experimental medicine
1987
Corpus ID: 22738028
MC-838, calcium (-)-N-[(S)-3-(N-cyclohexylcarbonyl-D-alanyl) thio]-2-methylpropionyl]-L- prolinate, is a new orally active…
Expand
1987
1987
Responses of renal, coronary and vertebral vasculatures to MC-838 and captopril in anesthetized dogs.
K. Noguchi
,
T. Kato
,
R. Sunagawa
,
M. Sakanashi
Pharmacology
1987
Corpus ID: 46862478
The regional hemodynamic effects of MC-838, a new angiotensin-converting enzyme inhibitor, and captopril at equidepressor doses…
Expand
1986
1986
Comparison of acute hemodynamic effects of MC-838, a new angiotensin-converting enzyme inhibitor, with captopril in anesthetized dogs.
K. Noguchi
,
T. Kato
,
R. Sunagawa
,
Y. Miyamoto
,
M. Sakanashi
Japanese Journal of Pharmacology
1986
Corpus ID: 31951057
Effects of a new angiotensin-converting enzyme inhibitor, N-[3-(N-cyclohexanecarbonyl-D-alanylthio)-2-methylpropanoyl] -L-proline…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE